Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda
Yahoo Finance
Read Full Article at Yahoo Finance →Ad Slot — In-Article (728x90)
A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.
This is a summary. For the full story, read the original article at Yahoo Finance.
Original source: Yahoo Finance